Exelixis | EXEL - Stock


Exelixis reported $26.6M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 108.67M 77.1M Jun/2026
Agios Pharmaceuticals USD 35.75M 665K Jun/2026
Akebia Therapeutics USD 13.02M 22K Jun/2026
Amgen USD 6.22B 34M Jun/2026
AstraZeneca USD 6.93B 362M Jun/2026
Bayer EUR 12.01B 321M Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Bristol-Myers Squibb USD 2.74B 19M Jun/2026
Cytokinetics USD 380K 226K Jun/2026
Eisai JPY 257.55B 21.09B Mar/2026
Eli Lilly USD 16.79B 2.26B Jun/2026
Exelixis USD 26.6M 4.92M Mar/2026
Genmab DKK 13M 1000K Jun/2025
Glaxosmithkline GBP 6.16B 39M Mar/2026
Incyte USD 112.54M 3.08M Jun/2026
Ionis Pharmaceuticals USD 50.83M 45.28M Jun/2026
MacroGenics USD 9.5M 1.59M Mar/2026
Merck USD 6.48B 179M Mar/2026
Moderna USD 280M 134M Jun/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 104.2M 39.7M Jun/2026
Novartis USD 6.22B 66M Jun/2026
Pfizer USD 9.94B 722M Jun/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Sanofi EUR 23.5B 812M Mar/2026
Takeda JPY 1.45T 50.64B Jun/2026
Ultragenyx Pharmaceutical USD 59M 4M Jun/2026